What gap in the spine innovation landscape is the Innovation Summit designed to address?

The spine innovation ecosystem is fragmented. Surgeons develop ideas. Investors deploy capital. Health systems control adoption. Payers determine reimbursement. But these stakeholders rarely sit in the same room for candid, operational conversations. The Innovation Summit fills that gap by creating a practical, lifecycle-focused forum — from capital formation to hospital inventory approval — where innovators can understand not just how to invent, but how to survive and scale in spine.

Unlike traditional scientific meetings, this summit focuses on capital strategy, regulatory nuance, coding, payer dynamics, and health system decision-making — the realities that determine whether an innovation succeeds or stalls.

Why is it important for NASS to convene surgeons, investors, health systems, and industry leaders in the same room?

Spine innovation no longer happens in silos. Success requires alignment across capital providers, clinicians, hospital systems, and payers. In short, Innovation in spine is ecosystem dependent. A device may be technically brilliant, but:

• Without aligned capital strategy, it may collapse under growth pressure.
• Without payer understanding, it may never be covered.
• Without health system alignment, it may never enter inventory.
• Without physician trust, it may never be adopted.

NASS is uniquely positioned as a neutral, trusted convener. By bringing these stakeholders into the same room for candid discussion, the Summit accelerates understanding, reduces friction, and improves the likelihood that promising technologies reach patients.

How does this Summit align with NASS’ broader role in shaping the future of spine care?

NASS has historically led in collaboration, multi-specialty education, clinical guidelines, coverage matters, advocacy, and evidence development. The Innovation Summit represents the next evolution — supporting spine innovation across the full lifecycle. This is not about promoting products. It is about:

Raising the sophistication of clinician-innovators. Improving capital efficiency in spine. Reducing friction between industry and health systems. Strengthening evidence, reimbursement, and adoption pathways. In many ways, this summit represents NASS stepping into its role as a strategic architect of the spine innovation ecosystem — not just an observer.

In your view, what has changed in the spine innovation ecosystem over the past few years that makes this conversation especially timely?

The spine innovation ecosystem has shifted dramatically:

Capital discipline has increased. Venture funding is more selective, with greater emphasis on clear reimbursement and adoption pathways. Hospitals have tightened value analysis processes. Clinical merit alone is no longer enough.

Private equity and strategic consolidation have accelerated. AI, robotics, and predictive analytics have raised the bar for what “innovation” means. Coding and payer scrutiny have intensified.

Innovation is no longer just about invention. It is about integration into complex systems. That makes this summit especially timely.

Day 1 focuses heavily on capital strategy and funding pathways. Why is understanding funding dynamics so critical for clinician-innovators and early-stage companies?

Funding sequence often determines success or failure in spine innovation.

Early capital decisions influence governance, timelines, growth pressure, and exit expectations. By addressing bootstrapping, surgeon angel investment, venture capital, private equity, and alternative funding models head-on, the Summit gives clinician-innovators and startups practical guidance on how to build sustainably.

The program includes candid discussions about hidden, but common funding missteps. How can unearthing these missteps change an innovator’s trajectory?

Most innovation failures are not clinical failures — they are strategic sequencing failures. By exposing these missteps: Overfunding too early; Hiring commercial infrastructure prematurely; Underestimating value analysis barriers; Misjudging regulatory timelines; … innovators can avoid preventable collapse. Transparency shortens the learning curve. And shortening that curve may preserve years of effort — and millions of dollars.

How are technologies such as AI, robotics, and predictive analytics influencing innovation and investor expectations in the spine space?

AI and robotics are shifting investor expectations in three ways:

Data are becoming central. Investors increasingly expect measurable outcomes, predictive modeling, and analytics integration.

Platform thinking is replacing single-product thinking. Health systems expect integration, not just hardware.

Innovations now must demonstrate workflow compatibility, data transparency, and more importantly, economic value! The bar for differentiation is higher than ever.

Day 2 Shifts to intellectual property, FDA pathways, coding, and payer considerations. Why is it essential to think about these issues early in the innovation process?

Because market access is not an afterthought — it’s foundational.

Patent strategy affects valuation. FDA pathway selection affects timeline and capital burn. Coding drives reimbursement. Payer positioning drives adoption.

Addressing these issues early protects enterprise value and prevents costly missteps.

How does bringing payer and health system perspectives into the conversation change the tone of the summit?

It shifts the conversation from theory to operational reality. Health system leaders explain how value analysis committees actually make decisions. Payers clarify what evidence is required for coverage. Surgeons discuss alignment and data transparency. The result is a practical, transparent dialogue focused on what truly moves innovation forward.